Currently, there are 255.92M common shares owned by the public and among those 199.70M shares have been available to trade.
However, the script later moved the day high at 9.98, up 8.39%. The company’s stock has a 5-day price change of 25.63% and 151.90% over the past three months. IOVA shares are trading 22.39% year to date (YTD), with the 12-month market performance up to 34.10% higher. It has a 12-month low price of $3.21 and touched a high of $10.31 over the same period. IOVA has an average intraday trading volume of 1.08 shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 23.05%, 27.53%, and 50.17% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Iovance Biotherapeutics Inc (NASDAQ: IOVA) shares accounts for 72.83% of the company’s 255.92M shares outstanding.
It has a market capitalization of $2.55B and a beta (3y monthly) value of 0.40. The earnings-per-share (ttm) stands at -$2.08. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.77% over the week and 7.36% over the month.
Analysts forecast that Iovance Biotherapeutics Inc (IOVA) will achieve an EPS of $Sunnova Energy International In for the current quarter, $12.15 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Innoviva, Inc. while analysts give the company a high EPS estimate of $Inventiva S.A. – American Depos. Comparatively, EPS for the current quarter was $IOVANCE BIOTHERAP.DL-,001 a year ago. Earnings per share for the fiscal year are expected to increase by 24.90%, and 27.89% over the next financial year.
Looking at the support for the IOVA, a number of firms have released research notes about the stock. Goldman stated their Buy rating for the stock in a research note on November 20, 2023, with the firm’s price target at $12.
